Piper Jaffray Downgrades Biogen (BIIB) to Neutral
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $216.78 +1.13%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Piper Jaffray downgraded Biogen (NASDAQ: BIIB) from Overweight to Neutral with a price target of $166.00 (from $175.00).
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $150.00 yesterday.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $150.00 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- JPMorgan Downgrades Bowman Consulting Group Ltd. (BWMN) to Underweight
- Navios Maritime Partners (NMM) PT Raised to $100 at Jefferies
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
Piper JaffraySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
